Rock Springs Capital Management LP Sells 108,019 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Rock Springs Capital Management LP trimmed its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 14.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 640,217 shares of the company’s stock after selling 108,019 shares during the quarter. Structure Therapeutics makes up 1.8% of Rock Springs Capital Management LP’s portfolio, making the stock its 18th biggest position. Rock Springs Capital Management LP’s holdings in Structure Therapeutics were worth $30,858,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GPCR. Sterling Capital Management LLC acquired a new position in Structure Therapeutics during the 1st quarter valued at about $28,000. State of Wyoming acquired a new stake in shares of Structure Therapeutics during the 2nd quarter worth approximately $28,000. CWM LLC raised its stake in shares of Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 125 shares during the last quarter. Assetmark Inc. lifted its holdings in Structure Therapeutics by 21.4% in the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after buying an additional 449 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in Structure Therapeutics in the fourth quarter valued at approximately $127,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR opened at $48.69 on Tuesday. The firm’s 50 day simple moving average is $45.67 and its 200 day simple moving average is $55.70. Structure Therapeutics Inc. Sponsored ADR has a fifty-two week low of $15.80 and a fifty-two week high of $94.90. The company has a market capitalization of $3.46 billion, a price-to-earnings ratio of -55.96 and a beta of -1.50.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. Equities research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current year.

Analysts Set New Price Targets

GPCR has been the topic of a number of recent research reports. Canaccord Genuity Group assumed coverage on shares of Structure Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating and a $101.00 price objective on the stock. Wall Street Zen downgraded Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. HC Wainwright reduced their price target on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, June 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Structure Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $110.55.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.